secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001178913-25-001673
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances
--------------------------------------------------------------------------------

- Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.
- Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.
- EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.
- Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.
- Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/0001178913-25-001673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/zk2533149.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer